$9M Parkinson's Research Grant Awarded to Team Including Arvinas
ARVN sits 41% above its 52-week low of $6.055.
Summary
An international team, including Arvinas, Inc., has been awarded a $9 million three-year research grant from Aligning Science Across Parkinson's (ASAP) and The Michael J. Fox Foundation. The collaboration will focus on investigating approaches to target toxic protein aggregates associated with Parkinson's disease. This grant provides external funding and validation for Arvinas's research efforts in neurodegeneration, a significant disease area with no current disease-modifying treatments. It strengthens the company's long-term research pipeline and potential for future therapeutic development.
At the time of this announcement, ARVN was trading at $8.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $553.6M. The 52-week trading range was $6.06 to $14.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Zawya.